Bicycle Therapeutics PLC
NASDAQ:BCYC
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
13.81
27.51
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Bicycle Therapeutics PLC
Bicycle Therapeutics PLC
Income from Continuing Operations
Bicycle Therapeutics PLC
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Income from Continuing Operations
-$166.3m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
N/A
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Income from Continuing Operations
-$151.1m
|
CAGR 3-Years
-142%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Exscientia PLC
NASDAQ:EXAI
|
Income from Continuing Operations
-£146m
|
CAGR 3-Years
-72%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Income from Continuing Operations
-$208.4m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Income from Continuing Operations
-£55.3m
|
CAGR 3-Years
9%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Income from Continuing Operations
£2.4m
|
CAGR 3-Years
-63%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-22%
|
|
Bicycle Therapeutics PLC
Glance View
Bicycle Therapeutics PLC, a pioneering force in biotechnology, was founded on a unique vision to transform medicine using a novel class of therapeutics known as Bicycles®. These are synthetic short peptides that combine the pharmacological capabilities of biologics with the manufacturing and distribution advantages of small molecules. The company's scientific ingenuity, originating from Cambridge, UK, has enabled it to engineer and develop a pipeline of drugs targeting areas with significant unmet medical needs, primarily in oncology and other severe diseases. Bicycle leverages its distinctive platform technology to design therapeutic candidates that offer high specificity and affinity, focusing on targets that have traditionally been challenging for conventional biologics and small molecules. Monetizing this innovative biotechnology hinges on Bicycle's strategic partnerships and collaborations with major pharmaceutical firms. These alliances allow the company to amplify its reach while sharing the risks and costs associated with drug development. By licensing their Bicycle® technology and therapeutic candidates to larger entities, Bicycle benefits from milestone payments and royalty streams, creating a sustainable revenue model. The company's revenue stream is thus a blend of upfront payments for access to their platform technology and the potential downstream success of these partners in developing and commercializing new therapeutic agents. Their unique approach and strong collaboration network position Bicycle Therapeutics at the forefront of next-generation drug discovery, striving to reshape treatment paradigms across multiple therapeutic areas.
See Also
What is Bicycle Therapeutics PLC's Income from Continuing Operations?
Income from Continuing Operations
-166.3m
USD
Based on the financial report for Sep 30, 2024, Bicycle Therapeutics PLC's Income from Continuing Operations amounts to -166.3m USD.
What is Bicycle Therapeutics PLC's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-37%
Over the last year, the Income from Continuing Operations growth was -3%. The average annual Income from Continuing Operations growth rates for Bicycle Therapeutics PLC have been -36% over the past three years , -37% over the past five years .
You don't have any saved screeners yet
